CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...

Novo Nordisk plans "all in" launch of Wegovy pill Novo Nordisk cuts U.S. price of injectable Wegovy Price will go down to $349 per month ahead of schedule CEO Doustdar highlights consumer weight-loss ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 ...

As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech declaring Novo's offer "superior"—even though it has already inked an ...

Drugmaker Pfizer PFE1.78%increase; green up pointing triangle on Friday sued obesity-drug developer Metsera and Novo Nordisk NOVO.B 3.31%increase; green up pointing triangle, seeking to block Metsera ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Matthew Herper covers ...

Pressured by its top shareholder, Novo Nordisk on Tuesday said key board members will be replaced. Pressured by its key shareholder, the Novo Nordisk Foundation, the company said its chairman, Helge ...

It appears problems at Novo Nordisk’s recently acquired manufacturing facility in Indiana aren’t going to be solved any time soon. The FDA has tagged the former Catalent facility with an official ...

Most effective drugs for obesity and its complications are semaglutide, tirzepatide, new European guideline says Certain GLP-1 drugs are best for specific complications The non-binding guideline ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...